Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Paclitaxel + Taladegib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Taladegib||LY2940680||SMO Inhibitor 16||Taladegib inhibits the Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (PMID: 22007748, Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1: Abstract #2819).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Paclitaxel + Taladegib||Phase I||Actionable||In a Phase I trial, combination of Taladegib and Taxol (paclitaxel) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 3 patients with advanced solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2594)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|